Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction

Steen Christian Kofoed; A Muhic; Lene Bæksgaard Jensen; M Jendresen; J Gustafsen; Jakob Holm; L Bardram; B Brandt; J Brenø; L B Svendsen

Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction

Steen Christian Kofoed, A Muhic, Lene Bæksgaard Jensen, M Jendresen, J Gustafsen, Jakob Holm, L Bardram, B Brandt, J Brenø, L B Svendsen

22 Citations (Scopus)

Abstract

Background and Aims: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In the pivotal Intergroup- 0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adenocarcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradiotherapy. Methods: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 patients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol. Results: Patients with positive node status in the resected specimen, the 3-year diseasefree survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24% and 37%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival. Conclusion: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.

Original language	English
Journal	Scandinavian Journal of Surgery
Volume	101
Issue number	1
Pages (from-to)	26-31
Number of pages	6
ISSN	1457-4969
Publication status	Published - Mar 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://sjs.sagepub.com/content/101/1/26.full.pdf

Cite this

@article{5ee5152a64134beb98df48fc4c50fcff,

title = "Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction",

abstract = "Background and Aims: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In the pivotal Intergroup- 0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adenocarcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradiotherapy. Methods: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 patients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol. Results: Patients with positive node status in the resected specimen, the 3-year diseasefree survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24% and 37%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival. Conclusion: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.",

author = "Kofoed, {Steen Christian} and A Muhic and Jensen, {Lene B{\ae}ksgaard} and M Jendresen and J Gustafsen and Jakob Holm and L Bardram and B Brandt and J Bren{\o} and Svendsen, {L B}",

year = "2012",

month = mar,

language = "English",

volume = "101",

pages = "26--31",

journal = "Scandinavian Journal of Surgery",

issn = "1457-4969",

publisher = "SAGE Publications",

number = "1",

}

TY - JOUR

T1 - Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction

AU - Kofoed, Steen Christian

AU - Muhic, A

AU - Jensen, Lene Bæksgaard

AU - Jendresen, M

AU - Gustafsen, J

AU - Holm, Jakob

AU - Bardram, L

AU - Brandt, B

AU - Brenø, J

AU - Svendsen, L B

PY - 2012/3

Y1 - 2012/3

N2 - Background and Aims: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In the pivotal Intergroup- 0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adenocarcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradiotherapy. Methods: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 patients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol. Results: Patients with positive node status in the resected specimen, the 3-year diseasefree survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24% and 37%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival. Conclusion: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.

AB - Background and Aims: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18% and 50%. In the pivotal Intergroup- 0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adenocarcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradiotherapy. Methods: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 patients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol. Results: Patients with positive node status in the resected specimen, the 3-year diseasefree survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24% and 37%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival. Conclusion: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.

M3 - Journal article

SN - 1457-4969

VL - 101

SP - 26

EP - 31

JO - Scandinavian Journal of Surgery

JF - Scandinavian Journal of Surgery

IS - 1

ER -

Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this